Migraine hampers a person’s activity as it interferes with your daily routine. Although, it is not life threatening, it sure does cramp your style. Migraines are excruciating and is altogether too common, but a breakthrough new research pinpoints to a cure.
For sufferers of migraine, one in 10 men and around two in 10 women, prevailing treatments prove to be ineffective at times and triggers unpleasant and severe side effects, according to The New Zealand Herald.
For 20 years now, scientists knew that migraines occur in people who have elevated levels CGRP, a pain-causing hormone, or calcitonin gene-related peptide.
A new drug classification called gepants, works by blocking CGRP motion at the hormone’s receptor in nerves, which were in the past testing phase for severe attack treatments, not as effective as expected.
But, a researcher team from University of Auckland in New Zealand, may have found the missing link.
Associate Professor Debbie Hay, of the university’s School of Biological Sciences, said in a statement, “We have discovered that CGRP activates a second target on the surface of pain-sensing nerve cells, called AMY1, which the gepants are not designed to block. Despite this hormone having such a clear role in migraines, why it’s been so hard to actually block it may be that we need to block two things and not just one.”
Dr Christopher Walker, a fellow researcher, said, there has been a high expectation for the CGRP-receptor blocking drugs, in treating migraine for a long time, but the presence of the second receptor might explain why targeting CGRP for migraine re has proved to be hard to exact.
Further study is now necessary to understand how the two receptors work may together, and the role each plays in nerves related to severe headache.
“But we are excited about the possibilities that AMY1 holds for treating migraine and even other types of pain. We need a new class of painkillers that people can take regularly opioids work but there are tolerance and addiction issues, and that’s not good enough.” Dr Walker said. According to the study published in the journal Annals of Clinical and Translational Neurology.